Please use this identifier to cite or link to this item:
|Title:||Beyond neurological disease: New targets for edaravone (Review)|
K. Ichi Kawahara
Yame Public Hospital
Kurume University School of Medicine
Kagoshima University Faculty of Medicine
Nishida Koutoku Hospital
Kohjin Co., Ltd.
Saiseikai Shiga Hospital
Omuta City General Hospital
|Keywords:||Biochemistry, Genetics and Molecular Biology|
|Citation:||International Journal of Molecular Medicine. Vol.28, No.6 (2011), 899-906|
|Abstract:||Free radicals play major roles in the pathogenesis of tissue damage in many diseases and clinical conditions, and the removal of free radicals may offer a treatment option. Several modulators of free radical scavenger pathways have been developed and some have progressed to clinical trials. One such agent, edaravone, was approved in 2001 in Japan for the treatment of cerebral infarction. It has since been shown that edaravone can diffuse into many organs and, in addition to its effects on hydroxyl radical removal, edaravone modulates inflammatory processes, matrix metalloproteinase levels, nitric oxide production, apoptotic cell death, and necrotic cell death. Edaravone also exerts protective effects in a number of animal models of disease and tissue damage, including models of myocardial, lung, intestinal, liver, pancreatic and renal injury. Together with the proven safety of edaravone following 9 years of use as a modulator of free radical scavenging pathways in neurological disease, these additional effects of edaravone suggest that it may offer a novel treatment for several non-neurological diseases and clinical conditions in humans.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.